Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

2020-03-28 03:55:23 | BioPortfolio


The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD


All Treatment Periods (P1 to P3) consist of 7 days of dosing (D1 to D7) with either:

- 10 mg foliglurax bis in die (BID) (treatment A)

- 30 mg foliglurax BID (treatment B)

- Placebo BID (treatment C)

Study Design


Parkinson Disease


Foliglurax 10 mg (treatment A), Foliglurax 30 mg (treatment B), Placebo (treatment C)


Biotrial Rennes




H. Lundbeck A/S

Results (where available)

View Results


Published on BioPortfolio: 2020-03-28T03:55:23-0400

Clinical Trials [13079 Associated Clinical Trials listed on BioPortfolio]

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

A study to learn how foliglurax binds in regions of the brain

Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects

The purpose of this study is to help determine which types of drugs that may interact with foliglurax

What the Body Does to Foliglurax in Healthy Volunteers

This study evaluates how the body takes up and gets rid of foliglurax after swallowing a liquid dose.

Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-...

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencin...

PubMed Articles [41652 Associated PubMed Articles listed on BioPortfolio]

Quantitative Electroencephalography Characteristics for Parkinson's Disease: A Systematic Review.

Individualized treatment guided by biomarkers certainly will play a crucial role in the more effective treatment of various neurological diseases in the near future. Identifying the electroencephalogr...

Parkinson's disease - heterogeneous and complex in its clinical presentation.

Parkinson's disease is the second most common neurodegenerative disease. Lewy bodies with alpha-synuclein as the major component and loss of dopaminergic nerve cells in substantia nigra are neuropatho...

Network Pharmacology Analysis on Zhichan Powder in Treatment of Parkinson's Disease.

Effective components and mechanism of action of Zhichan Powder in treatment of Parkinson's disease were researched at a systematic level.

Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.

Parkinson's disease (PD) is a progressive neurodegenerative condition affecting approximately 185,000 people in the UK. No drug has been proven to slow disease progression. Epidemiological and pre-cli...

Improvement of oral function and hygiene in Parkinson's disease: a randomized controlled clinical trial.

Parkinson's disease (PD) is a progressive neurodegenerative disorder. It is associated with reduced oral health and impaired orofacial function, but besides recommendations of dental visits and drooli...

Medical and Biotech [MESH] Definitions

Drugs used in the treatment of movement disorders. Most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of Parkinson disease (ANTIPARKINSON AGENTS) and those for the tardive dyskinesias.

A precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Administration of DL-threo-3,4-dihydroxyphenylserine has been claimed to result in an improvement in this phenomenon but controlled studies have failed to demonstrate improvement. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

Procedures, surgery, or other treatment without consent of person or persons receiving treatment.

Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed.

More From BioPortfolio on "Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects"

Quick Search

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Searches Linking to this Trial